SWOG clinical trial number
30904
A Prospective Randomized Phase III Study Comparing Radical Surgery to Elective Kidney Sparing Surgery for Low Stage Renal Cell Carcinoma
Closed
Phase
Published
Research committees
Genitourinary Cancer
Eligibility Criteria Expand/Collapse
Pt must have solitary T1-T2 renal tumors, suspicious for renal adenocarcinoma in the presence of a normal contralateral kidney. Tumor must be well located so that surgery can be safely done in healthy tissue; should not exceed 5 cm in diameter; must be single on CT scan; does not show evidence of invasion of the perirenal fat (T1-T2) on CT or IVU. Pt must have N0, M0 disease, be fit for surgery with a WHO performance status of less than 2. Pt must not have a solitary kidney, von Hippel-Lindau disease, multifocal disease, T3-T4 tumors, clinical presence of distant or lymphatic mets nor a WHO performance status of greater than 2.
Publication Information Expand/Collapse
2014
PMid: PMID23850254 | PMC number: not available
Other Clinical Trials
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
8%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA8185
Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase